Cite
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
MLA
Nazzareno Galiè, et al. “Temporary Treatment Interruptions with Oral Selexipag in Pulmonary Arterial Hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) Study.” The Journal of Heart and Lung Transplantation, vol. 37, Mar. 2018, pp. 401–08. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....be69c5078106dd42c98d2c92fd6e19d4&authtype=sso&custid=ns315887.
APA
Nazzareno Galiè, Ioana R. Preston, Marius M. Hoeper, Lilla Di Scala, Lewis J. Rubin, G. Simonneau, Vallerie V. McLaughlin, Sean Gaine, Harrison W. Farber, Olivier Sitbon, Kelly Chin, Richard N. Channick, R Preiss, Victor F. Tapson, Irene M. Lang, & Hossein Ardeschir Ghofrani. (2018). Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. The Journal of Heart and Lung Transplantation, 37, 401–408.
Chicago
Nazzareno Galiè, Ioana R. Preston, Marius M. Hoeper, Lilla Di Scala, Lewis J. Rubin, G. Simonneau, Vallerie V. McLaughlin, et al. 2018. “Temporary Treatment Interruptions with Oral Selexipag in Pulmonary Arterial Hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) Study.” The Journal of Heart and Lung Transplantation 37 (March): 401–8. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....be69c5078106dd42c98d2c92fd6e19d4&authtype=sso&custid=ns315887.